pembrolizumab
Merck's Keytruda Improves Disease-Free Survival in Allcomers in Adjuvant NSCLC Trial
In an interim analysis, the drug also improved disease-free survival in patients with high PD-L1 expression but failed to reach statistical significance.
Novartis, BeiGene Ink Licensing Deal for TIGIT Inhibitor Ociperlimab
Novartis will pay BeiGene $300 million upfront for rights to develop and commercialize the agent, which BeiGene is studying with a checkpoint inhibitor in NSCLC and solid tumors.Â
PD-L1 Cutoff for TNBC Keytruda Benefit Confirmed in KEYNOTE Analyses, But Questions Linger
Findings confirmed advanced TNBC patients with PD-L1 10 or above benefit from Keytruda, but other data show PD-L1 doesn't predict benefit in earlier-stage TNBC.Â
NGM Biopharmaceuticals, Merck to Study ILT2/4 Inhibitor Plus Keytruda in Solid Tumors
The companies inked a collaboration to study the drug combination in advanced solid tumors with elevated expression of ILT2 and ILT4.
Celularity Garners IND Clearance for NK-Cell Therapy, Immunotherapy Combo Trial
With the FDA's permission, the company will now explore the activity of its off-the-shelf cell therapy with Keytruda and Herceptin in advanced gastric cancer patients.